{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:34:12Z","timestamp":1758814452846},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVE:<\/jats:title>\n            <jats:p>To evaluate whether prophylactic dronabinol, a synthetic tetrahydrocannabinol, reduces pain during medical abortion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS:<\/jats:title>\n            <jats:p>We conducted a randomized, double-blind, placebo-controlled trial of women undergoing medical abortion with mifepristone and misoprostol up through 70 days of gestation. All participants received 800 mg of ibuprofen and were randomized to either 5 mg of oral dronabinol or a placebo 30 minutes before misoprostol administration. Participants used a text messaging service to report pain on a numeric rating scale from 0 to 10 (0=no pain, 10=worst pain). The primary outcome was maximum pain experienced during the 24 hours after misoprostol administration. Secondary outcomes were pain scores at 0, 6, and 24 hours after misoprostol administration; maximum anxiety and nausea scores; use of additional pain medication; reported side effects; and satisfaction (yes or no). We needed 68 participants (34 per group) to have 80% power to detect a 2-point difference in maximum pain on a numeric rating scale.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>From November 2018 to May 2019, we randomized 70 women (dronabinol=35, placebo=35). Participants in the study arms had comparable baseline characteristics. We found no difference between groups in the median maximum pain score reported (dronabinol 7 [interquartile range 6\u20138], placebo 7 [interquartile range 5\u20138], <jats:italic toggle=\"yes\">P<\/jats:italic>=.82) or median pain scores at any timepoint. Groups were also no different in mean maximum anxiety (dronabinol 3.33 [SD 3.06], placebo 3.23 [SD 2.53], <jats:italic toggle=\"yes\">P<\/jats:italic>=.88) or nausea scores (dronabinol 2.21 [SD 2.32], placebo 2.72 [SD 2.64], <jats:italic toggle=\"yes\">P<\/jats:italic>=.41). Most women were satisfied with their pain management (76% dronabinol, 82% placebo, <jats:italic toggle=\"yes\">P<\/jats:italic>=.51).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>Dronabinol does not reduce the maximum level of pain experienced by women undergoing medical abortion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n            <jats:p>ClinicalTrials.gov, NCT03604341.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aog.0000000000003850","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:41:03Z","timestamp":1588970463000},"page":"1289-1295","source":"Crossref","is-referenced-by-count":8,"title":["Cannabinoids for Pain Control During Medical Abortion"],"prefix":"10.1097","volume":"135","author":[{"given":"Alyssa Covelli","family":"Colwill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Alton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula H.","family":"Bednarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa L.","family":"Bayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharti","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Beardsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Edelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6811a1","article-title":"Abortion surveillance\u2014United States, 2016","volume":"68","author":"Jatlaoui","year":"2019","journal-title":"MMWR Surveill Summ"},{"key":"R2-20230711","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1080\/14767058.2017.1344963","article-title":"US trends in abortion and preterm birth","volume":"31","author":"Malosso","year":"2018","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1471-0528.1994.tb11948.x","article-title":"Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure","volume":"101","author":"el-Refaey","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.contraception.2008.09.001","article-title":"Two-pill regimens of misoprostol after mifepristone medical abortion through 63 days' gestational age: a randomized controlled trial of sublingual and oral misoprostol","volume":"79","author":"Raghavan","year":"2009","journal-title":"Contraception"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-0528.2000.tb13273.x","article-title":"Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial","volume":"107","year":"2000","journal-title":"BJOG"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jpain.2012.07.007","article-title":"Geographic variation in opioid prescribing in the U.S","volume":"13","author":"McDonald","year":"2012","journal-title":"J Pain"},{"key":"R7-20230711","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/AOG.0000000000003576","article-title":"Opioid analgesia for medical abortion: a randomized controlled trial","volume":"134","author":"Colwill","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R9-20230711","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00406-019-00984-4","article-title":"How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review","volume":"269","author":"Hoch","year":"2019","journal-title":"Eur Arch Psychiatr Clin Neurosci"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/393377","article-title":"Morning sickness: a mechanism for protecting mother and embryo","volume":"75","author":"Flaxman","year":"2000","journal-title":"Q Rev Biol"},{"key":"R13-20230711","first-page":"9","article-title":"Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers","volume":"9","author":"Oh","year":"2017","journal-title":"Clin Pharmacol"},{"key":"R14-20230711","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0010-7824(00)00181-5","article-title":"Timing of pain and bleeding after mifepristone-induced abortion","volume":"62","author":"De Nonno","year":"2000","journal-title":"Contraception"},{"key":"R15-20230711","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0885-3924(03)00162-3","article-title":"Clinically important changes in acute pain outcome measures: a validation study","volume":"25","author":"Farrar","year":"2003","journal-title":"J Pain Symptom Manage"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S1526-5900(03)00716-8","article-title":"Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain","volume":"4","author":"Jensen","year":"2003","journal-title":"J Pain"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/AOG.0000000000002787","article-title":"Prophylactic pregabalin to decrease pain during medication abortion: a randomized controlled trial","volume":"132","author":"Friedlander","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S1928","article-title":"Cannabinoids in the management of difficult to treat pain","volume":"4","author":"Russo","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-017-3387-5","article-title":"A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics","volume":"80","author":"Badowski","year":"2017","journal-title":"Canc Chemother Pharmacol"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"E2478","DOI":"10.3390\/molecules23102478","article-title":"Cannabinoid delivery systems for pain and inflammation treatment","volume":"23","author":"Bruni","year":"2018","journal-title":"Molecules"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.neurol.2018.07.011","article-title":"Dronabinol use in France between 2004 and 2017","volume":"175","author":"Lejczak","year":"2019","journal-title":"Rev Neurol (Paris)"},{"key":"R23-20230711","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1097\/00126334-200010001-00012","article-title":"Potential interventions for HIV\/AIDS wasting: an overview","volume":"25","author":"Abrams","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/17512433.2017.1292849","article-title":"Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?","volume":"10","author":"Maccarrone","year":"2017","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T21:25:52Z","timestamp":1689110752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000003850"}},"subtitle":["A Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000003850","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]}}}